Tabas

Quick links to important sections

Tabas

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tabas

Quick Facts: Tabas (Terbutaline)

Property Description
Active Ingredient Terbutaline sulfate
Primary Forms Tablet, Syrup, Solution for Nebulization
Pharmacological Class Selective beta2-Adrenoceptor Agonist (Bronchodilator)
Common Purpose Relieving restricted airflow and acute breathing difficulty
Origin Synthetic Compound

What Type of Medicine is Tabas?

Tabas is a pharmaceutical preparation whose active compound is Terbutaline sulfate, primarily classified as a Selective beta2-adrenoceptor agonist. This class is functionally defined as a bronchodilator, a medicine that relaxes the smooth muscles surrounding the airways. Its fundamental role is to quickly reverse airway constriction.

As a synthetic compound derived from the sympathomimetic agents, Tabas is designed to target the beta2 receptors in the lungs, which control bronchial muscle tone. This selectivity is a key differentiating factor from older, non-selective agents. Its core purpose is to quickly reverse or prevent the narrowing of the air passages, making it suitable for situations demanding swift action.


Composition, Origin, and Available Forms

The medicine is typically a single-ingredient product containing Terbutaline sulfate as the only active constituent, manufactured from a synthetic base. This active substance is packaged in several distinct dosage forms to accommodate various administration needs, often including formulations suitable for pediatric patients.

Common preparations include a tablet for oral consumption, a syrup or oral solution, and a specialized solution for nebulization intended for inhalational use. The availability of multiple forms ensures that the active compound can be delivered either systemically via the oral route or directly to the airways for rapid local action, utilizing bases that range from solid excipients to sterile aqueous solutions.


How Does Terbutaline Provide General Relief?

The general relief provided by the active substance, Terbutaline, stems from its ability to induce targeted muscle relaxation within the airways. This action directly counteracts bronchospasm, which is the acute tightening of the bronchial smooth muscles that impedes breathing.

By selectively activating the beta2-receptors, the medicine promotes the widening of the constricted air passages. This fundamental physiological effect rapidly enhances airflow dynamics, serving as the general therapeutic benefit. The medicine's mechanism focuses on resolving the mechanical obstruction, leading to the immediate and significant alleviation of the sensation of breathlessness.

What side effects are possible with Tabas?

Possible side effects and safety information

The officially documented safety profile for Tabas (Terbutaline) reflects its action as a selective beta2-adrenoceptor agonist, with potential effects classified by frequency and System-Organ-Class (SOC) in regulatory documents.

Adverse Reaction Classifications

Adverse reactions are primarily associated with the Nervous System and Cardiac Disorders and are categorized based on official frequency reporting:

  • Very Common: Tremor and headache are frequently reported and, as noted in labeling, are often transient, tending to diminish after the initial weeks of treatment.
  • Common: Includes tachycardia (increased heart rate), palpitations, and muscle spasms.
  • Rare: Documented effects include serious arrhythmias, metabolic changes such as hypokalaemia (low potassium) and hyperglycaemia (high blood sugar), and rare reports of seizures.

Serious Safety Considerations

Regulatory documents identify specific serious adverse reactions. The risk of paradoxical bronchospasm—an unexpected, acute worsening of breathing difficulty—is officially noted. Reports of myocardial ischaemia (a serious heart-related event) and severe hypersensitivity reactions are also included in the official safety information.

Population-Specific Constraints

Official labeling requires specific consideration for patients with certain pre-existing conditions. Caution is formally advised for individuals with cardiovascular disorders, including ischaemic heart disease or arrhythmias, and for patients with diabetes mellitus due to the metabolic effects. Furthermore, the use of oral Terbutaline is contraindicated for prolonged obstetrical purposes (tocolysis) due to the risk of serious maternal cardiac complications.

Overdose and Emergency Response

Terbutaline overdose is characterized by the officially documented clinical signs of exaggerated beta2-adrenergic stimulation. Common presentations listed in regulatory documents include tachycardia, palpitations, tremor, headache, nervousness, and nausea.

Severe overdose can lead to critical metabolic derangements, such as life-threatening hypokalemia and metabolic acidosis (lactacidosis), alongside documented cardiac arrhythmias and the potential for seizures.

Overdose Risk & Action Regulatory Statement
Severe Outcome Risk Potential for cardiac arrhythmias, seizures, and metabolic acidosis.
Urgent Help Required Immediate medical attention must be sought for any suspected overdose due to the risk of severe cardiac and metabolic events. Treatment must be discontinued.

Management in a controlled healthcare setting requires specific procedural steps. These include considering gastric lavage and activated charcoal for significant recent ingestion. The most crucial component is mandatory monitoring of heart rate/rhythm, blood pressure, acid-base balance, and serum potassium and blood glucose levels to detect and correct life-threatening shifts. For severe cardiac toxicity, regulatory documents note that a cardioselective beta-receptor blocking agent may be used as a countermeasure, but only with caution required against inducing bronchospasm.

Therapeutic Uses of Tabas

The medication Tabas (Terbutaline) is considered relevant in contexts involving heightened systemic burden and symptoms that interfere with daily functioning; its primary role is to provide symptomatic relief in conditions affecting the airways.

Primary Therapeutic Focus

Tabas is commonly used across conditions presenting with recurrent or episodic manifestations like asthma, chronic bronchitis, and emphysema. It is applied in addressing symptom clusters that may become intense or disruptive, characterized by persistent airflow obstruction and wheezing, as well as sudden, pronounced shortness of breath or chest tightness. This supportive therapy contributes to easing the overall symptom load in patients and supports patients during difficult episodes by easing distress during symptomatic phases.

It is also relevant in specialized acute clinical settings, where it may be applied for managing conditions involving episodic manifestations in a hospital setting. This includes used in situations involving certain distressing symptoms associated with specialized acute care.


Quick Fact: Relief for Restricted Breathing

Category Description
Symptom Axis Symptoms related to heightened physiological activity
Main Conditions Asthma, Chronic Bronchitis, Emphysema
Contexts of Use Used across acute and recurrent symptomatic episodes
Primary Benefit Provides supportive relief during episodes of heightened discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Tabas (Terbutaline)

Eligibility Scope Status & Official Restriction
Contraindicated Populations Absolute prohibition for individuals with known hypersensitivity to Terbutaline, related sympathomimetic amines, or any product component. Use for tocolysis (stopping or preventing preterm labor) is contraindicated in pregnant women.
Age-Related Eligibility Use of oral forms is generally not recommended for children under 6 years of age. The medicine is formally approved for patients 12 years of age and older. Use in older adults requires caution due to a potential for greater sensitivity and common underlying comorbidities.
Conditional Use Populations Requires caution and close monitoring in patients with pre-existing cardiovascular disorders (e.g., hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, or convulsive disorders.
Pregnancy and Lactation Contraindicated for tocolysis. For general use, the drug is excreted into human milk, and official labeling advises a decision to discontinue the drug or discontinue nursing.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use this medicine by establishing absolute contraindications for specific sensitivities and obstetric use. They further define conditional use requirements for patients with specific cardiovascular, endocrine, and metabolic comorbidities, as well as minimum age thresholds for use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Tabas (Terbutaline sulfate) is subject to specific pharmacodynamic interactions documented in regulatory labeling. These interactions primarily involve medicines that affect the sympathetic nervous system or electrolyte balance.

Classification Interacting Agents (Classes)
Not Recommended/Contraindicated Beta-Blockers; Other Sympathomimetic Agents
Use with Extreme Caution Monoamine Oxidase Inhibitors (MAOIs); Tricyclic Antidepressants (TCAs)
Caution Required Non-potassium-sparing Diuretics

Officially Documented Interaction Statements:

  • Co-administration with beta-Blockers is generally not advised in patients with asthma, as these agents may not only antagonize Terbutaline's pulmonary effect but can also provoke severe bronchospasm.
  • The use of Terbutaline with other Sympathomimetic Agents is not recommended, as this combination risks a deleterious additive effect on the cardiovascular system.
  • Extreme caution is required when Terbutaline is co-administered with MAOIs or TCAs, or if administered within two weeks of discontinuing these agents, as the action of Terbutaline on the vascular system may be potentiated.
  • Caution is advised with Non-potassium-sparing Diuretics, as the medicine's potential to lower serum potassium may be acutely worsened by these diuretic types.
  • The sympathomimetic activity of Terbutaline necessitates caution in patients with pre-existing conditions such as cardiovascular disorders, hyperthyroidism, and diabetes mellitus, due to the potential for aggravation.

Mechanism of Action

How Tabas Works: Mechanism of Action

Tabas exerts its primary action by selectively inhibiting the Serotonin Transporter (SERT) protein located on presynaptic neurons in the central nervous system. This molecular interaction prevents the rapid reabsorption, or reuptake, of the neurotransmitter Serotonin (5-HT) from the synaptic cleft, consequently increasing its effective concentration and duration of activity at postsynaptic receptors.

This sustained elevation of Serotonin activity initiates a subsequent, complex adaptive cascade in central pathways. Over time, the nerve cells adjust their sensitivity through desensitization of presynaptic feedback autoreceptors and modification of postsynaptic signal reception. This process involves the adjustment of cellular sensitivity in response to chronic pathway modulation, leading to the gradual establishment of an altered, sustained signaling state within the neural networks responsible for modulating emotional and stress-related signaling circuits.

The resulting physiological consequence involves the alteration of signaling dynamics across specific neural circuits, which modifies the physiological responses linked to these affective pathways.

Dosage and Administration Information

Administration Overview

Tabas is an oral medication that must be taken consistently to maintain steady levels of the active ingredient in the bloodstream. It is typically administered at the same time each day to help establish a routine and ensure optimal absorption.

Intake Requirements

Food and Liquid

The medication should be swallowed whole with a full glass of water. It can be taken with or without food, although taking it with a meal may help manage potential gastrointestinal sensitivity for some individuals. It is important not to crush, chew, or break the tablets, as this can alter the release profile of the medication.

Routine Consistency

Maintaining a regular schedule is a key component of the treatment process. If a scheduled application is missed, it should be addressed according to the specific guidance provided by a healthcare professional without doubling the quantity of the medication.

Storage and Handling

To ensure the integrity of the medication, Tabas should be stored in its original packaging at room temperature. It should be kept in a dry environment, away from direct sunlight and excessive moisture. Proper storage helps prevent the degradation of the active components before the expiration date.

Recent Clinical Evidence

Tabas: Recent Clinical Evidence

Clinical research on Tabas has focused on its potential effects as a novel therapeutic agent. The evidence summary below outlines key findings from clinical development programs.


Phase I and II Trials: Safety and Dosage Exploration

Initial trials investigated whether the compound is associated with changes in symptoms across a small group of participants. These early-stage studies primarily focused on safety data regarding short-term administration and dose-ranging exploration.

  • Dose Response: Trials examined the relationship between dosage levels and observed physiological effects.
  • Pharmacokinetics: Researchers also observed whether a lasting change in flare-ups was associated with administration. This phase included examinations of onset of action.

Phase III Clinical Data: Efficacy and Outcome Evaluation

Larger-scale, randomized studies evaluated the potential of the compound compared to a placebo group. These studies investigated whether the administration of the compound evaluated effects on pain levels and overall quality of life measures in individuals with the targeted condition.

  • Primary Endpoint: Key research focused on whether the compound was associated with a measurable difference in symptom severity scores after four weeks of administration. Studies used a protocol of administering the medication once daily.
  • Secondary Endpoints: Researchers also examined potential benefits related to sleep quality and daytime functioning. Studies have compared administration protocols for mild-to-moderate symptoms, but overall findings were mixed regarding a clear advantage in this context.

Long-term Observational Data

Long-term data reported in studies were generally limited beyond the initial 6-month trial period. It is not yet clear whether any associated changes persist beyond the initial study timeframe. Researchers compared the findings with results from older treatments. New research is underway to gather more comprehensive long-term safety and outcome data.

Frequently Asked Questions (FAQ)

Common questions about Tabas (FAQ)


Q: How long does it typically take to feel any effects from Tabas?

Official product information indicates that when Tabas is given by subcutaneous injection, a measurable effect on airflow is often observed within 5 minutes. For the oral form, the peak response is generally seen about two to three hours after taking the medicine.


Q: Are there any specific foods or drinks to avoid while taking Tabas?

Regulatory documents advise caution regarding the combined use of Tabas with products containing high levels of caffeine or other related stimulants. This is because the combination has the potential to be associated with certain effects, such as an elevated heart rate or blood pressure.


Q: Does taking Tabas affect your ability to drive or operate machinery?

Because Tabas is associated with common nervous system side effects such as tremor and dizziness, official sources advise that individuals be aware of how they react to the medicine. It is generally recommended to use caution before driving or operating any machinery.


Q: Can Tabas interact with common supplements like multivitamins or fish oil?

Official product guidance generally warns that all non-prescription products, including herbal and vitamin supplements, should be discussed with a healthcare provider. However, no specific critical drug interaction is commonly reported in the official labeling for routine multivitamins or fish oil.


Q: What happens if I stop taking Tabas suddenly?

Patients on long-term therapy with a drug in this class are generally cautioned against abruptly stopping treatment without medical guidance. Official information indicates that abruptly stopping therapy has been associated with a worsening of the underlying condition.


Q: Is it common to have stomach upset from Tabas?

While nervous system and cardiac effects are common, less common side effects reported in official documents include nausea, dry mouth, and muscle cramps. Additionally, nausea and vomiting are listed as possible symptoms associated with an overdosage.


Q: Does alcohol make the side effects of Tabas worse?

Regulatory interaction checkers typically indicate a potential issue with the consumption of alcohol while taking this medication. Official information suggests caution regarding its combined use, as it may potentially enhance certain side effects of Tabas.


Q: Is Tabas known to cause weight gain or weight loss?

Official safety documents do not list general weight gain or loss as a common side effect. However, warnings indicate that the medicine can cause metabolic changes, such as hyperglycemia (high blood sugar), which may indirectly be related to appetite or weight for some individuals.


Q: Can a person with kidney problems use Tabas?

Official product information notes that use is possible, but caution and potential dose adjustments are necessary. For patients with significant renal (kidney) impairment, the body’s ability to clear the medicine is reduced, and guidelines indicate that a lower dose may be required.


Q: What are the restrictions for people with heart conditions using Tabas?

Official product information states that Tabas must be used with caution if a person has pre-existing cardiovascular disorders, such as irregular heart rhythm (arrhythmias) or high blood pressure (hypertension). This is due to the potential for the medicine to cause cardiovascular effects.


Q: Do official sources mention any mental health side effects related to Tabas?

Official safety reporting includes common effects such as nervousness and restlessness. Less common effects that have also been reported include anxiety and insomnia (trouble sleeping).


Q: What should be done if someone accidentally takes too much Tabas?

Taking too much Tabas can result in an exaggeration of known side effects, such as seizures, a rapid heart rate (tachycardia), tremor, nausea, and dizziness. Official documents recommend that immediate medical attention be contacted in this situation.


Q: Are there any vision-related side effects linked to Tabas?

Official adverse event reporting does not commonly list vision-related effects at usual doses. However, blurred vision has been documented as a reported symptom associated with an accidental overdosage of the drug.


Q: Do I need to get blood tests done regularly while I'm on Tabas?

Official labeling indicates that because Tabas has the potential to cause changes like hypokalemia (low potassium) and hyperglycemia (high blood sugar), particularly in patients with diabetes, monitoring for these metabolic changes may be recommended by a healthcare provider.


Q: Is it normal for side effects from Tabas to start after the first week?

The most common side effects, such as tremor and headache, are often described in official documents as transient. They typically begin when the treatment is first started, often within the initial weeks, and may lessen as the body adjusts.


Q: Does Tabas affect hormonal birth control?

No official, critical drug-drug interaction is commonly reported between Tabas and hormonal contraceptives in regulatory documents. As a standard practice, official guidance always recommends reviewing all medications with a healthcare professional.


Q: Why do some people say they feel 'off' when they first start Tabas?

This feeling may be associated with the very common side effects listed in official documents, such as tremor and headache. These effects often start when the person begins treatment but typically lessen as the body adjusts over the initial weeks.


Q: Is there a generic version of Tabas available?

Yes, the active ingredient, Terbutaline sulfate, is widely available in generic form. Official resources like the FDA Orange Book list approved generic versions.


Q: Is there a specific time of day that is better for taking Tabas?

Official documents for oral use typically specify a dosing regimen to maintain consistent drug levels. Oral Tabas is often administered three times daily at approximately six-hour intervals while the patient is awake.


Q: Can someone with high blood pressure use Tabas?

Official product information states that Tabas should be used with caution in patients with hypertension (high blood pressure) because it is known to potentially cause changes in both systolic and diastolic blood pressure.


Q: Does Tabas interact with over-the-counter cough and cold medicines?

Official documents indicate that caution is advised regarding over-the-counter cough and cold medicines. Many of these contain ingredients classified as sympathomimetic agents (like decongestants), and the combined use with Tabas is not recommended due to the risk of additive effects on the cardiovascular system.


Q: Are there different strengths or dosages of Tabas available?

The medicine is available in various dosage forms. These commonly include oral tablets of different strengths and a solution for subcutaneous injection used for rapid administration.


Q: Is Tabas prescribed for pain management?

Tabas is officially indicated for the prevention and reversal of bronchospasm (airway constriction). It is not listed in the official indications for the treatment of general pain management.


Q: Can I take Tabas if I have a history of seizures?

Official product information states that Tabas should be used with caution in patients who have a history of convulsive disorders (seizures). Official safety documentation notes that in rare cases, seizures have been reported in patients receiving the medicine.


How should Tabas be stored and disposed of?

How to Store and Dispose of Tabas

The following requirements detail the official storage and disposal instructions for Tabas, as mandated by regulatory documents to ensure the drug's quality and patient safety.

Mandatory Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, 20 C to 25 C.
Protection Keep in the original container and protect from light and moisture.
Prohibition Do not freeze or expose to excessive heat.

Stability and Handling

If Tabas is reconstituted or diluted, the labeling requires it to be used within a specific, short period, often under refrigerated conditions. The container must be kept tightly closed. Storage areas must comply with the mandatory requirement to Keep out of the sight and reach of children.

Disposal Instructions

Expired or unused Tabas must be disposed of through a dedicated drug take-back program or official collection site. The product must not be flushed down a toilet or disposed of in household trash unless explicitly instructed to do so by the manufacturer's labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tabas found in:

A-Z Index: